18F-AV-1451 Autopsy Study

• Status: Completed
• Trial end date: 2018-07-15
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Avid Radiopharmaceuticals

Criteria

Inclusion Criteria:

• Have a projected life expectancy of ≤ 6 months

• Can tolerate a 20 minute PET scan

• Give informed consent or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the State in which they die

Exclusion Criteria:

• Aggressively being treated with life sustaining measures

• Known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment

• Clinically significant infectious disease

• Currently receiving any investigational medications except with permission from the study sponsor

• Participated in an experimental study with an amyloid or tau targeting agent

• Suspected encephalopathy due to alcoholism or end-stage liver disease

• Females of childbearing potential

• History of risk factors for Torsades de Pointes or are currently taking medication known to cause QT prolongation